Sign Up
|
Sign In
Home
US Market
UK Market
News
My Portfolio
Forex
Forum
Cockpit
EuroTrader
Home
»
World
»
North America
»
United States
»
Merck & Company Inc Common S
Merck & Company Inc Common S
MRK
(NYSE)
Overview
Discussions
Advanced chart
News
Historical data
Recommendations
To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed.
$
37.60
Updated
01:04:03
Change %
-0.6%
Change
-0.2210
Volume
9,300,133
High
$
37.89
Low
$
37.55
Open
$ 37.73
Prev close
$ 37.82
# of shares
-
Market cap
-
Intraday
Market closed
Tech analysis
Market is closed, opens at 14:30
Price development
Latest
1 week
1 month
3 mon
6 mon
1 year
37.60
-0.4%
-2.9%
-1.6%
11.2%
1.5%
Insufficient flash player version
News about Merck & Company Inc Common S
Subscribe To RSS Feed
Local
International
Announcements
21 May
J&J's Simponi Helps Colitis Patients In Clinical Trial
08 May
WSJ BLOG/Health: A.M Vitals: "Good" Cholesterol Drug Fails; Alzheimer's and Depression Linked
07 May
2nd UPDATE: Abbott To Pay $1.6 Billion To Settle Depakote Marketing Probes
04 May
House Panel Seeks Information From Drug Cos. On Health Law Agreements With White House -Bloomberg
02 May
WSJ BLOG/Health: Studies Shine Light on How Vioxx Raises Heart Risks
02 May
WSJ BLOG/Health: Studies Shine Light on How Vioxx Raises Heart Risks
30 April
Applications Given Early Antitrust Clearance
27 April
UPDATE: US Judge Upholds Validity Of Merck's Vytorin Patent
27 April
US Judge Upholds Validity Of Merck's Vytorin Patent
27 April
US Stocks Rise, Set For Biggest Weekly Advance Since In Six Weeks
25 March
Zacks Analyst Blog Highlights: Merck, Sanofi-Aventis, Eli Lilly, Pfizer and Johnson & Johnson
18 March
Le Comité des médicaments à usage humain (CHMP) émet un avis favorable sur la nouvelle pilule contraceptive NOMAC-E2
14 February
Zacks Analyst Blog Highlights: MannKind Corporation, Merck, Pfizer, TOTAL S.A. and Suncor Energy
14 January
Critical Alerts for Merck, Anadarko Petroleum, Silver Wheaton, Cree, and Limited Brands Released by Seven Summits Research
21 December
SIMPONI™ (golimumab) recibe la opinión positiva del CHMP en Europa para la reducción del índice de progresión del daño articular
20 December
SIMPONI™ (golimumab) riceve un parere positivo da parte del Comitato per i medicinali per uso umano (CHMP) in Europa per la ridu
20 December
SIMPONI™ (golimumab) reçoit un avis favorable du CPMUH en Europe pour la réduction du taux de progression des lésions articulair
20 December
SIMPONI™ (golimumab) ontvangt positief advies van CHMP in Europa voor verlaging van progressiepercentage gewrichtsaandoeningen b
14 December
Critical Alerts for Merck, Vale, F5 Networks, Ensco, and Cypress Semiconductor Released by Seven Summits Research
09 December
LEAD 1 Bayer, Novartis en lice pour des actifs Sanofi/Merck
No news for this instrument
More news
Company profile
No description
Version: LiveBranchBuild_20120516.1 - EUROWEB1 - 2012-05-22 02:40:06 - 2012-05-22 01:40:06 - 1000 - Website: OKAY